Browsing Tag
United States
1074 posts
Why Chord Energy is selling 32,000 Marcellus acres to POSCO for $550m
Chord Energy Corporation is selling its entire non-operated Marcellus position to POSCO International Corporation for $550 million, leaving the producer focused exclusively on the Williston Basin.
Why Michael Dell’s DFO Management is backing a $7.7bn insurance brokerage buyout
Sequence Holdings and Michael Dell’s DFO Management will take The Baldwin Group private in a $7.7 billion deal built around insurance consolidation, technology and artificial intelligence.
Russian satellites may have helped Iran sharpen attacks on US forces, raising new Moscow-Tehran concerns
Russian satellites may have helped Iran sharpen attacks on US forces. Find out what the intelligence claims mean for Moscow, Tehran and Washington.
5E Advanced Materials wins court approval for Searles Valley critical minerals acquisition
5E Advanced Materials has won court approval to acquire Searles Valley assets, adding boron production, infrastructure and new financing obligations.
Rocket Lab secures financing for $8bn Iridium deal as bridge risk falls away
Rocket Lab has fully funded its $8 billion Iridium acquisition, replacing bridge debt with equity and retained Iridium financing ahead of a 2027 close.
GSK agrees up to $750m Chimagen deal to deepen multiple myeloma pipeline
GSK is paying up to $750 million for a trispecific multiple myeloma asset, with early clinical data set to determine whether the deal creates value.
INVE Technologies completes Identiv IoT sale as Trackonomy physical AI strategy takes shape
INVE Technologies exits its IoT operations for Trackonomy equity, shifting toward compliance software acquisitions and a new physical AI strategy.
Waystar explores potential sale as healthcare software valuation gap draws buyer interest
Waystar is exploring a potential sale as strong margins and recurring revenue clash with a stock price still well below its 52-week high.
Jazz Pharmaceuticals closes $820m Actio Biosciences deal to deepen epilepsy pipeline
Jazz Pharmaceuticals buys Actio Biosciences for $820 million upfront, betting on ABS-1230 while early-stage clinical risk remains the key test.
The Baldwin Group agrees $7.7bn take-private as AI productivity bet deepens
The Baldwin Group’s $7.7 billion take-private pairs an 88% premium with heavy leverage, making AI-led productivity and organic growth the key value tests.